Anaxis Pharma

TLX-101-Tx (Iodofalan, 131I-labeled iodophenylalanine) is a radiopharmaceutical being developed by Lacuna Pharma Pty Ltd as an adjunct to lomustine for recurrent glioblastoma. The program combines a small-molecule radiopharmaceutical with the established alkylating agent lomustine (GLEOSTINE, approved oral chemotherapy) in a Phase 3 pivotal trial designated IPAX-3. The trial is a global, multicenter, prospective, controlled, open-label study comparing TLX-101-Tx plus lomustine versus lomustine monotherapy in patients with radiographically confirmed recurrent glioblastoma at first recurrence. Glioblastoma represents one of the most aggressive primary brain malignancies, with limited treatment options at recurrence and poor prognosis. The combination approach aims to improve outcomes beyond standard-of-care lomustine alone. Lomustine itself has been approved in the United States by the FDA under multiple manufacturers (Azurity and Carnegie) with application numbers ANDA219265 and NDA017588. The program is currently in active Phase 3 development with the IPAX-3 trial as the pivotal efficacy and safety study. No regulatory approval has yet been disclosed, and peak sales projections and consensus positioning are not yet available.

Recurrent glioblastoma carries a dismal prognosis, with median overall survival of approximately 6–9 months following first recurrence when treated with standard chemotherapy alone. Current treatment options are limited and include re-resection, re-radiation, and chemotherapy with agents such as lomustine or temozolomide, none of which substantially improve survival. The unmet medical need is substantial: patients with recurrent glioblastoma lack effective, well-tolerated therapies that can meaningfully extend survival or improve quality of life. The competitive landscape includes multiple approaches—surgical resection, radiation therapy (including GammaTile implantation), dendritic cell immunotherapy, and small-molecule chemotherapies (enzastaurin, edotecarin, cediranib, temozolomide, and other agents)—yet none have achieved definitive superiority over standard care. Lacuna Pharma's strategy of combining a radiopharmaceutical with lomustine represents a differentiated approach, potentially leveraging targeted radiation delivery to enhance cytotoxicity. The patient population is substantial: thousands of patients annually develop recurrent glioblastoma in major markets. Commercial significance is high given the lack of effective alternatives and the willingness of oncologists and patients to adopt novel therapies for this uniformly fatal disease. Success in IPAX-3 could establish a new standard of care and create a meaningful commercial opportunity in a high-unmet-need indication.

Drug Class: Radiopharmaceutical (TLX-101-Tx, Iodofalan) combined with alkylating chemotherapy (lomustine).

Modality: Small-molecule radiopharmaceutical; lomustine is a small-molecule alkylating agent.

Mechanism of Action: Not yet disclosed for TLX-101-Tx. Lomustine is a nitrosourea alkylating agent that cross-links DNA, inducing cell death.

Molecular Target: Not yet disclosed for TLX-101-Tx.

Route of Administration: TLX-101-Tx administered as solution for injection; lomustine administered orally (GLEOSTINE).

Related Therapies: Temozolomide (standard recurrent glioblastoma chemotherapy), dendritic cell immunotherapy, small-molecule kinase inhibitors (cediranib, enzastaurin, edotecarin), and radiation-based approaches.

Regulatory Status of Lomustine Component: FDA-approved in the United States; marketed as GLEOSTINE under multiple manufacturers (Azurity Pharmaceuticals, Carnegie Pharma).

Patent Status: Not yet disclosed.

FDA Status: TLX-101-Tx (Iodofalan) regulatory status not yet disclosed. Lomustine (GLEOSTINE) is FDA-approved; application numbers ANDA219265 (Azurity) and NDA017588 (Carnegie) are on file with the FDA.

EMA, PMDA, NMPA Status: Not yet disclosed.

Clinical Trial Registration: IPAX-3 trial registered under NCT identifier 2025-521785-10-00.

Approval Timeline: No regulatory approval date or filing date has been disclosed. The Phase 3 IPAX-3 trial is the pivotal study required for potential regulatory submission.

Strategic Positioning: Lacuna Pharma's combination of a radiopharmaceutical with lomustine represents a differentiated approach to recurrent glioblastoma, leveraging both targeted radiation and chemotherapy. The strategy acknowledges that lomustine monotherapy has limited efficacy, and the addition of a radiopharmaceutical may provide incremental benefit through dual mechanisms of action.

Competitive Implications: The program faces significant competition from multiple modalities (kinase inhibitors, immunotherapy, radiation, and combination chemotherapy). Success in IPAX-3 would need to demonstrate superiority over standard lomustine and potentially over emerging competitors such as cediranib or combination temozolomide-pembrolizumab. The open-label design may introduce bias; blinded comparisons would strengthen evidence.

Regulatory Pathway: IPAX-3 is positioned as a pivotal trial for potential regulatory submission. The use of an established comparator (lomustine) and a well-defined patient population (first recurrence) are appropriate. Regulatory approval would likely require demonstration of clinically meaningful improvement in overall survival or progression-free survival with acceptable tolerability.

Future Catalysts: Key milestones include interim efficacy and safety readouts from IPAX-3, final efficacy data, regulatory submissions (FDA, EMA), and potential label expansion to earlier lines of therapy or combination with other agents. Commercial success will depend on trial outcomes, regulatory approval, reimbursement decisions, and adoption by neuro-oncologists.

Unresolved Questions: The mechanism of action of TLX-101-Tx, its molecular target, and the rationale for the radiopharmaceutical component remain undisclosed. Clarity on these aspects would strengthen the scientific case for the program.